Marinomed Biotech AG
🇦🇹XWBO.MARIAustriaHealthcare
Price€4.000.00 (0%)
Latest anomalies
Neutral 0 detected in the last 120 days
- High: 1
- Medium: 5
- Low: 0
Return on assets: a sudden drop below its trailing quarter average
Current ratio: below the level we flag as a liquidity warning
EBITDA margin: a sudden drop below its trailing quarter average
Leverage ratio: a sudden spike above its trailing quarter average
Net profit margin: a sudden drop below its trailing quarter average
Free with a Finzer account.
Profile
- Healthcare
- Biotechnology
- Austria
Identity
- Exchange
- Vienna Stock Exchange . XWBO
- Type
- Stock
- ISIN
- ATMARINOMED6
- CUSIP
- Not reported
Company
- Employees
- 33
- Headquarters
- Korneuburg, Austria
- Website
- https://www.marinomed.com
- CEO
- Mr. Andreas Grassauer Ph.D.
Market
- Shares outstanding
- 1.8M
- Market cap
- €7.36M
Highlights
No high and low reported for today's session.
- Market cap
- €7.36M
- EPS LTM
- -€3.30calculatedCalculated by Finzer, not reported by the data provider.
- P/E LTM
- -1.21calculatedCalculated by Finzer, not reported by the data provider.
- Div yield
- Not reported
Fundamentals (LTM)
- Revenue
- €11.6M-12.83%down year on year
- Net income
- -€6.07M-13.39%down year on year
- Gross margin
- 17.46%-34.69%down year on year
- Free cash flow
- -€5.46M-132.54%down year on year
Latest news
News is not sourced for this exchange.
Business summary
Marinomed Biotech AG is a company in the healthcare sector, listed on Vienna Stock Exchange (Austria) under the ticker MARI. Its market capitalisation is €7.36M, from 1.8M shares outstanding, as of . Across the 251 trading sessions to the shares traded between €2.20 and €21.00, and the last close of €4.00 sits 10% of the way up that range. The company is headquartered in Korneuburg, Austria, employs about 33 people and is led by Mr. Andreas Grassauer Ph.D..
Marinomed Biotech AG, a biopharmaceutical company, develops therapeutic products for indications in virology and immunology in Austria, other European countries, and internationally. It operates through Virology, Immunology, and Other segments. The company's products pipeline includes Budesolv for the treatment of allergic rhinitis; Tacrosolv, which is in Phase II clinical trial for inflammatory eye diseases; and Inhaleen for viral infection of the upper and lower respiratory tract. It also provides Solv4U which offers formulation development and biopharmaceutical testing services. It has a technology partnership with SPH Sine Pharmaceutical Laboratories Co. Ltd. The company was formerly known as Marinomed Biotechnologie GmbH and changed its name to Marinomed Biotech AG in June 2017. Marinomed Biotech AG was incorporated in 2006 and is headquartered in Korneuburg, Austria.